Navigation Links
Kosan Announces Third Quarter 2007 Financial Results
Date:11/8/2007

e timing thereof) and potential safety, efficacy, commercialization and other characteristics of Kosan's product candidates, including tanespimycin, alvespimycin and KOS-1584. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, risks related to Kosan's expectation that additional financing will be required, Kosan's past dependence on its collaboration with Roche for development of its epothilone product candidates and current dependence on Pfizer for development of KOS- 2187, Kosan's ability to enter into new partnering arrangements and the highly uncertain nature of the progress and results of Kosan's testing of its product candidates, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate additional clinical trials, continue clinical development, obtain the requisite regulatory approvals or result in a marketable product, competition and other risks detailed from time to time in Kosan's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Selected Financial Information

Condensed Statements of Operations

(in thousands, except per share amounts)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Total revenues $1,947 $2,169 $17,071 $7,796

Operating expenses:'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... March 15 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: AOB ), ("the Company" or ... of prescription and over the counter ("OTC"),products, today announced financial results for the fourth quarter and ... ... ...
... ATLANTA, Georgia , March 14, 2010 Cardiovascular ... 2 diabetes patients with,atherogenic dyslipidemia, the common combination of elevated ... levels of high-density,lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L ... 20 of these patients need,to be treated for 5 years ...
... Borough of Manhattan ... , ... 12, 2010 -- Borough of Manhattan Community College (BMCC) science major Kimberly Thompson ... well as $5,000 as an overall Grand Prizewinner., , , , ,Thompson--the contest,s only awardee ...
Cached Biology Technology:American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 2American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 3American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 4American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 5American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 6American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 7American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 8American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 9American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 10American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 11American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results 12ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 2ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 3ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 4ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 5ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 6ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 7ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 8ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 9BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2
(Date:4/15/2014)... Western Reserve University dental researchers have found a less ... the mouth to study how the mouth,s natural defenses ... specialized immune cells (white blood cells known as "leukocytes") ... reject foreign tissues, such as in failed organ transplantsresearchers ...
(Date:4/15/2014)... form could help reduce side effects by targeting the drugs ... nanoparticles that deliver one or two chemotherapy drugs, but it ... any more than that in a precise ratio. , Now ... nanoparticles, making it much easier to include three or more ...
(Date:4/15/2014)... , By 2050, deforestation could cause temperatures in the ... would intensify warming caused by greenhouse gases by half, ... of Leuven, Belgium. , Explosive population growth and inefficient ... in Central Africa. A team of researchers from the ...
Breaking Biology News(10 mins):New method isolates immune cells for researchers to study how they ward off oral diseases 2Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Study: Deforestation could intensify climate change in Congo Basin by half 2
... dirty air caused more than $193 million in hospital-based ... help for problems such as asthma and pneumonia that ... new RAND Corporation study. Researchers estimate that exposure ... nearly 30,000 emergency room visits and hospital admissions over ...
... Atrazine, one of the world,s most widely used pesticides, ... frogs, emasculating three-quarters of them and turning one in ... University of California, Berkeley, biologists. The 75 percent ... their inability to reproduce in the wild, reports UC ...
... 1, 2010) -- The use of recombinant proteins, ... is a simple yet powerful strategy to study the ... spectrometry rather than western blotting extends the identification of ... complex mixtures. But this increased sensitivity can lead ...
Cached Biology News:Study finds dirty air in California causes millions worth of medical care each year 2Study finds dirty air in California causes millions worth of medical care each year 3Pesticide atrazine can turn male frogs into females 2Pesticide atrazine can turn male frogs into females 3Pesticide atrazine can turn male frogs into females 4Protein-bait interactions, display libraries featured in Cold Spring Harbor Protocols 2
Whole rabbit blood (any breed, either sex) is collected at the time of slaughter and processed immediately at 4C, bottled, frozen and stored at -70C....
Animal Origin Free...
Goat polyclonal to PINX1 ( Abpromise for all tested applications). entrezGeneID: 54984 SwissProtID: Q548A5...
Request Info...
Biology Products: